Oxford Pharmascience - Interim results 2016 | Broadcast | BRR Media

Oxford Pharmascience - Interim results 2016

OXP Tue, 13 Sep 2016, 12:15pm BST

Marcelo Bravo, Chief Executive Officer discusses their unaudited interim results for the six months to 30 June 2016. Highlights include the substantial progress being made in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen.

Marcelo Bravo

Chief Executive Officer

Company Events - OXFORD PHARMASCIENCE GROUP

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Company update

Marcelo Bravo, Chief Executive Officer

Wed, 25 Jan 2017, 11:00am GMT

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Interim results 2016

Marcelo Bravo, Chief Executive Officer

Tue, 13 Sep 2016, 12:15pm BST

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience Group plc - Company update...

Marcelo Bravo, Chief Executive Officer

Fri, 22 Apr 2016, 10:00am BST

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Oxford Pharmascience - Successful completion of PoC for...

Marcelo Bravo, Chief Executive Officer

Thu, 5 Nov 2015, 8:00am GMT

<img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img alt="" width="36" height="36" data-src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" class="lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw=="><noscript><img src="https://www.brrmedia.co.uk/wp-content/themes/salient/img/play-button.png" alt="" width="36" height="36">

Preliminary PK Data & Initiation of Further Study...

Marcelo Bravo, Chief Executive Officer

Wed, 12 Aug 2015, 3:00pm BST